Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1


Journal

International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 04 03 2020
revised: 26 09 2020
accepted: 07 11 2020
pubmed: 28 11 2020
medline: 7 8 2021
entrez: 27 11 2020
Statut: ppublish

Résumé

This study aimed to investigate the in vitro activity of taniborbactam (VNRX-5133), a novel broad-spectrum bicyclic boronate, against NDM-1 and Q119E, Q119K, Q119C, Q119F, Q119V, and Q119Y NDM-1 variants, which showed an increased activity towards some β-lactams, including cefepime. Inhibition kinetic assays were spectrophotometrically performed using cefepime (50 μM) as the reporter substrate and 80 nM of each enzyme. Taniborbactam behaves as a competitive inhibitor towards NDM-1 and NDM-1 Q119 variants with lower Ki values (range 3-16 nM). The phenotypic profile was assessed in both Enterobacterales clinical isolates and engineered Escherichia coli BL21(DE3) strains by conventional broth microdilution procedures according to the Clinical and Laboratory Standards Institute (CLSI). Taniborbactam at a fixed concentration of 4 mg/L was able to restore activity of cefepime in 24 of 26 Enterobacterales clinical isolates harbouring metallo-β-lactamases with MIC The inhibition level of NDM enzymes provided by taniborbactam protects the antibacterial activity of cefepime from this important metallo-β-lactamase.

Identifiants

pubmed: 33246038
pii: S0924-8579(20)30439-8
doi: 10.1016/j.ijantimicag.2020.106228
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Borinic Acids 0
Carboxylic Acids 0
beta-Lactamase Inhibitors 0
Cefepime 807PW4VQE3
taniborbactam 8IGQ156Z07
beta-Lactamases EC 3.5.2.6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106228

Informations de copyright

Copyright © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

Auteurs

Alessandra Piccirilli (A)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Bernardetta Segatore (B)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Fabrizia Brisdelli (F)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Gianfranco Amicosante (G)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Mariagrazia Perilli (M)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy. Electronic address: perilli@univaq.it.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Biofilms Candida albicans Quorum Sensing Candida glabrata Menthol

Classifications MeSH